The first Ukrainian patients have begun treatment for prostate cancer with an innovative Bayer drug, which was approved in September 2025.
As the company told the “Interfax-Ukraine” news agency, the drug is currently available to patients. Its efficacy and safety profile have been confirmed by international clinical trials.
Prostate cancer remains one of the most common cancers among men.
As reported, Bayer forecasts growth in its pharmaceutical business starting in 2027, with an increase in operating margin to 30% by 2030. Additionally, the company plans to develop five key therapeutic areas, including cardiology—specifically secondary stroke prevention—comprehensive treatment of chronic kidney disease, oncology—including treatment of metastatic hormone-sensitive prostate cancer—women’s health, and menopause symptom management.
The international company Bayer operates in the healthcare and agriculture sectors. In fiscal year 2025, the Bayer Group employed over 88,000 people, and sales exceeded EUR 45.6 billion. R&D expenditures, excluding special items, reached over EUR 5.8 billion.
Bayer Ukraine is part of the global Bayer AG group, headquartered in Leverkusen, Germany. The company has been operating in Ukraine since 1992. It is represented by the following divisions: Pharmaceuticals, Consumer Health, and Agriculture.
